Trafficking of CAR-Engineered human T cells following regional or systemic adoptive transfer in SCID beige mice

Journal of Clinical Immunology

Volumn 31, Issue 4, 2011, Pages 710-718

  Parente Pereira, Ana Caterina ^a   Burnet, Jerome ^b   Ellison, David ^b   Foster, Julie ^b   Davies, David Marc ^a   Van Der Stegen, Sjoukje ^a   Burbridge, Sophie ^a   Chiapero Stanke, Laura ^a   Wilkie, Scott ^a   Mather, Stephen ^b   Maher, John ^a,c,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^d KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptor; SPECT CT

Indexed keywords

CHIMERIC ANTIBODY; MUCIN 1; T LYMPHOCYTE ANTIGEN; TROPOLONE IN 111;

ABSORPTION; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL LABELING; CELL MIGRATION; CELL TRACKING; CONTROLLED STUDY; CYTOTOXICITY; ENGRAFTMENT; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN TARGETING; RISK REDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR XENOGRAFT;

EID: 85027918156     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9532-8     Document Type: Article

References (43)

1. Sprangers B, Van Wijmeersch B, Fevery S, Waer M, Billiau AD. Experimental and clinical approaches for optimization of the graftversus- leukemia effect. Nat Clin Pract Oncol. 2007;4:404-14. (Pubitemid 47039691)
2. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233-40.
3. Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum Gene Ther. 2009;20:1240-8.
4. Sadelain M. T-cell engineering for cancer immunotherapy. Cancer J. 2009;15:451-5.
5. Davies DM, Maher J. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T-cells. Arch Immunol Ther Exp. 2010;58:165-78.
6. Varela-Rohena A,Molloy PE, Dunn SM, Li Y, SuhoskiMM, Carroll RG, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med. 2008;14:1390-5.
7. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527-36. (Pubitemid 43927099)
8. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol.2002;20:70-5. (Pubitemid 34044918)
9. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12:933-41. (Pubitemid 41614489)
10. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17:1453-64.
11. Murphy WJ, Tian ZG, Asai O, Funakoshi S, Rotter P, Henry M, et al. Chemokines and T lymphocyte activation: II. Facilitation of human T cell trafficking in severe combined immunodeficiency mice. J Immunol. 1996;156:2104-11. (Pubitemid 26087440)
12. Taub DD, Tsarfaty G, Lloyd AR, Durum SK, Longo DL, Murphy WJ. Growth hormone promotes human T cell adhesion and migration to both human and murine matrix proteins in vitro and directly promotes xenogeneic engraftment. J Clin Invest.1994;94:293-300. (Pubitemid 24218104)
13. Nervi B, Rettig MP, Ritchey JK, Wang HL, Bauer G, Walker J, et al. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp Hematol. 2007;35:1823-38. (Pubitemid 350117108)
14. Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, Punzalan B, et al. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med. 2009;15:338-44.
15. Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med. 2008;49:1162-70. (Pubitemid 351948026)
16. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, et al. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol. 2007;179:3332-41.
17. Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, et al. Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor. J Immunol. 2008;180:4901-9.
18. Davies DM, Wilkie S, Foster JM, Delinassios G, Chiapero-Stanke L, Burbridge S, et al. Targeting the extended Erbb receptor family using chimeric antigen receptor (CAR)-grafted T-cells as a treatment for head and neck cancer. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, AACR, Washington, DC, USA, 17-21 April 2010. Abstract no. 1932.
19. Pittet MJ, Grimm J, Berger CR, Tamura T, Wojtkiewicz G, Nahrendorf M, et al. In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci USA.2007;104:12457-61. (Pubitemid 47206159)
20. Wingens M, Walma T, van Ingen H, Stortelers C, van Leeuwen JE, van Zoelen EJ, et al. Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity. J Biol Chem. 2003;278:39114-23. (Pubitemid 37229068)
21. Wilkie S, Burbridge SE, Chiapero-Stanke L, Pereira AC, Cleary S, van der Stegen SJ, et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem. 2010;285:25538-44.
22. Read EJ, Keenan AM, Carter CS, Yolles PS, Davey RJ. In vivo traffic of indium-111-oxine labelled human lymphocytes collected by automated apheresis. J Nucl Med. 1990;31:999-1006. (Pubitemid 20186243)
23. Wagstaff J, Gibson C, Thatcher N, Ford WL, Sharma H, Crowther D. Human lymphocyte traffic assessed by indium 111oxine labelling: Clinical observations. Clin Exp Immunol. 1981;43:443-9. (Pubitemid 11130406)
24. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, et al. Tumor localization of adoptively transferred indium-111 labelled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol. 1989;7:250-61. (Pubitemid 19048459)
25. Smith ME, Ford WL. The recirculating lymphocyte pool of the rat: A systematic description of the migratory behaviour of recirculating lymphocytes. Immunology. 1983;49:83-94. (Pubitemid 13120367)
26. Looney MR, Thornton EE, Sen D, Lamm WJ, Glenny RW, Krummel MF. Stabilized imaging of immune surveillance in the mouse lung. Nat Methods. 2011;8:91-6.
27. Hamann A, Klugewitz K, Austrup F, Jablonski-Westrich D. Activation induces rapid and profound alterations in the trafficking of T cells. Eur J Immunol. 2000;30:3207-18.
28. Staunton DE, Dustin ML, Erickson HP, Springer TA. The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell.1990;61:243-54.
29. Aird WC. Phenotypic heterogeneity of the Endothelium. 1. Structure, Function and Mechanisms. Circ Res. 2007;100:158-73. (Pubitemid 46208717)
30. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843-51.
31. Heslop HE. Safer CARs. Mol Ther. 2010;18:661-2.
32. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol. 2006;24: E20-2.
33. Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nährig J, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2- overexpressing breast cancer. Cancer Immunol Immunother.2008;57:271-80. (Pubitemid 350159915)
34. Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, et al. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci USA. 2010;107:14286-91.
35. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18:666-8.
36. Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP. The liver as a site of T-cell apoptosis: Graveyard, or killing field? Immunol Rev. 2000;174:47-62. (Pubitemid 30201378)
37. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002;13:1971-80. (Pubitemid 35341038)
38. Lo AS, Taylor JR, Farzaneh F, Kemeny DM, Dibb NJ, Maher J. Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Mol Immunol. 2008;45:1276-87.
39. Schliemann C, Palumbo A, Zuberbühler K, Villa A, Kaspar M, Trachsel E, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood. 2009;113:2275-83.
40. Cappuccini F, Lucci 3rd JA, Dett CA, Gatanaga M, Ininns EK, Gatanaga T, et al. Trafficking of syngeneic murine lymphokine activated killer T cells following intraperitoneal administration in normal and tumor bearing mice. Gynecol Oncol. 1992;46:163-9.
41. Markman M. Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: Efficacy, toxicity, and future directions. Rev Recent Clin Trials. 2007;2:169-73. (Pubitemid 47554837)
42. Van Elssen CH, Frings PW, Bot FJ, Van de Vijver KK, Huls MB, Meek B, et al. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology. 2010;57:597-606.
43. Simpson BJ, Phillips HA, Lessells AM, Langdon SP, Miller WR. c-erbB growth-factor-receptor proteins in ovarian tumours. Int J Cancer. 1995;64:202-6.